Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $635.40 MXN
Change Today 0.00 / 0.00%
Volume 0.0
BAX* On Other Exchanges
Symbol
Exchange
New York
Berlin
SIX Swiss Ex
Mexico
As of 4:09 PM 08/24/15 All times are local (Market data is delayed by at least 15 minutes).

baxter international inc (BAX*) Snapshot

Open
$635.40
Previous Close
$635.40
Day High
$635.40
Day Low
$635.40
52 Week High
08/21/15 - $652.98
52 Week Low
11/4/14 - $505.29
Market Cap
346.6B
Average Volume 10 Days
5.6K
EPS TTM
--
Shares Outstanding
545.5M
EX-Date
09/2/15
P/E TM
--
Dividend
$0.46
Dividend Yield
4.75%
Current Stock Chart for BAXTER INTERNATIONAL INC (BAX*)

baxter international inc (BAX*) Related Businessweek News

View More BusinessWeek News

baxter international inc (BAX*) Details

Baxter International Inc., develops, manufactures, and markets products for people with hemophilia, immune disorders, infectious diseases, kidney disease, trauma, and other chronic and acute medical conditions. The company’s BioScience segment processes recombinant and plasma-based proteins to treat hemophilia and other bleeding disorders; plasma-based therapies to treat immune deficiencies, alpha-1 antitrypsin deficiency, burns and shock, and other chronic and acute blood-related conditions; and biosurgery products. The Medical Products segment manufactures intravenous (IV) solutions and administration sets, premixed drugs and drug-reconstitution systems, pre-filled vials and syringes for injectable drugs, IV nutrition products, infusion pumps, and inhalation anesthetics; and products and services related to pharmacy compounding, drug formulation and packaging technologies, as well as to treat renal disease, irreversible kidney failures, and other renal therapies. This segment also offers products for peritoneal dialysis, in-center and home hemodialysis, continuous renal replacement therapy, and other dialysis services. It markets its products through direct sales force, independent distributors, drug wholesalers, and specialty pharmacy to hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors’ offices, clinical and medical research laboratories, and patients. The company operates in the United States, Europe, the Middle East, Africa, the Asia-Pacific, Latin America, and Canada. It has collaboration with Merrimack Pharmaceuticals, Inc. to develop and commercialize MM-398 injection; CTI BioPharma Corp. to develop and commercialize pacritinib; Coherus Biosciences, Inc. and Momenta Pharmaceuticals, Inc. to develop and commercialize biosimilars; JW Holdings Corporation for parenteral nutritional products; and Onconova Therapeutics, Inc. for rigosertib anti-cancer compound. The company was founded in 1931 and is based in Deerfield, Illinois.

66,000 Employees
Last Reported Date: 02/26/15
Founded in 1931

baxter international inc (BAX*) Top Compensated Officers

Chairman, Chief Executive Officer and Preside...
Total Annual Compensation: $1.5M
Corporate Vice President, General Counsel and...
Total Annual Compensation: $651.0K
Corporate Vice President of Human Resources
Total Annual Compensation: $525.3K
Compensation as of Fiscal Year 2014.

baxter international inc (BAX*) Key Developments

Takeda to expand rights related to Nanotherapeutics’ Vero cell technology platform

[1]Progressive Media - Company News August 27, 2015 Takeda to expand rights related to Nanotherapeuticsâ?? Vero cell technology platform SECTION:Â OTHER CONTRACT SERVICES; Product Developments LENGTH:Â 231 words HIGHLIGHT:Â Takeda Pharmaceutical has entered into an agreement to acquire expanded commercialization and technology access rights related to Nanotherapeuticsâ?? Vero cell technology platform, a cell culture-based platform for vaccine production. Nanotherapeutics acquired Vero cell technology from Baxalta, formerly Baxter International's BioScience division.

Baxter International Inc. and Water Street Healthcare Partners Announce FDA Approval of CEFAZOLIN 2 Gram Premix

Baxter International Inc. and Water Street Healthcare Partners announced the United States Food and Drug Administration has approved CEFAZOLIN Injection in GALAXY Container (2 g/100 mL), which is Baxter’s flexible container that uses the company’s proprietary aseptic filling manufacturing processes. CEFAZOLIN injection is a cephalosporin antibacterial indicated for preoperative prophylaxis treatment. When used for preoperative prevention, it may reduce the incidence of certain postoperative infections for high-risk patients undergoing surgical procedures. CEFAZOLIN injection has been on the FDA’s drug shortage list for more than one year due to high demand. Baxter anticipates launching CEFAZOLIN injection 2 gram frozen premix in its GALAXY container in the United States in the fourth quarter of 2015. CEFAZOLIN injection 2 gram represents the first of nine molecules actively under development to provide healthcare providers needed injectable formulations of essential drugs frequently used in critical care settings through Baxter’s development partnership with Celerity Pharmaceuticals, LLC, a company of Water Street, a strategic investor focused exclusively on the healthcare industry. Cefazolin injection is a cephalosporin antibacterial indicated for preoperative prophylaxis. Use an alternative cefazolin product when lengthy surgical procedures require supplemental doses and when postoperative dosing is required. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Cefazolin injection and other antibacterial drugs, Cefazolin injection should be used only to prevent infections that are proven or strongly suspected to be caused by bacteria.

Baxter International Inc. Declares Quarterly Dividend, Payable on October 1, 2015

Baxter International Inc. declared a regular quarterly dividend of $0.115 per Baxter common share. This cash dividend is payable on October 1, 2015 to shareholders of record as of September 4, 2015.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BAX*:MM $635.40 MXN 0.00

BAX* Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Boston Scientific Corp $16.85 USD -0.22
Cerner Corp $62.15 USD -0.98
Fresenius Medical Care AG & Co KGaA €68.11 EUR -0.109
St Jude Medical Inc $71.34 USD -1.28
Zimmer Biomet Holdings Inc $103.96 USD -0.41
View Industry Companies
 

Industry Analysis

BAX*

Industry Average

Valuation BAX* Industry Range
Price/Earnings 12.3x
Price/Sales 1.3x
Price/Book 2.6x
Price/Cash Flow 9.7x
TEV/Sales 0.0x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BAXTER INTERNATIONAL INC, please visit www.baxter.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.